
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 22, 2026

INTUITIVE SURGICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-30713
(Commission
File Number)

77-0416458
(I.R.S. Employer
Identification No.)

1020 Kifer Road
Sunnyvale, California 94086
(Address of Principal Executive Offices) (zip code)

Registrant's telephone number, including area code: (408) 523-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	ISRG	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On January 22, 2026, Intuitive Surgical, Inc. (“Intuitive”) issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of the press release is furnished hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of Intuitive under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

d) Exhibits.

Exhibit No. Description

99.1 [Press release issued by Intuitive Surgical, Inc., dated January 22, 2026](#)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 22, 2026

INTUITIVE SURGICAL, INC.

By: /s/ JAMIE E. SAMATH

Name: Jamie E. Samath

Title: Executive Vice President, Chief Financial Officer

Contact: Investor Relations
(408) 523-2161

INTUITIVE ANNOUNCES FOURTH QUARTER EARNINGS

SUNNYVALE, CALIF. January 22, 2026 – Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2025.

Q4 Highlights

- Worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%.
- The Company placed 532 da Vinci surgical systems, compared with 493 in the fourth quarter of 2024. The fourth quarter 2025 da Vinci surgical system placements included 303 da Vinci 5 systems, compared with 174 in the fourth quarter of 2024. The Company placed 42 Ion endoluminal systems, compared with 69 in the fourth quarter of 2024.
- The Company grew its da Vinci surgical system installed base to 11,106 systems as of December 31, 2025, an increase of 12% compared with 9,902 as of December 31, 2024. The Company grew its Ion endoluminal system installed base to 995 systems as of December 31, 2025, an increase of 24% compared with 805 as of December 31, 2024.
- Fourth quarter 2025 revenue of \$2.87 billion increased 19% compared with \$2.41 billion in the fourth quarter of 2024.
- Fourth quarter 2025 GAAP net income attributable to Intuitive was \$795 million, or \$2.21 per diluted share, compared with \$686 million, or \$1.88 per diluted share, in the fourth quarter of 2024.
- Fourth quarter 2025 non-GAAP* net income attributable to Intuitive was \$914 million, or \$2.53 per diluted share, compared with \$805 million, or \$2.21 per diluted share, in the fourth quarter of 2024. Fourth quarter 2025 non-GAAP* net income attributable to Intuitive included tax benefits of \$0.11 per diluted share associated with the release of unrecognized tax benefits.
- Fourth quarter 2025 expenses included a \$70 million contribution to the Intuitive Foundation compared to a \$45 million contribution to the Intuitive Foundation in the fourth quarter of 2024.

Q4 Financial Summary

Gross profit, income from operations, net income attributable to Intuitive Surgical, Inc., and net income per diluted share attributable to Intuitive Surgical, Inc. are reported on a GAAP and non-GAAP* basis. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.

Fourth quarter 2025 revenue was \$2.87 billion, an increase of 19% compared with \$2.41 billion in the fourth quarter of 2024. The higher fourth quarter revenue was driven by growth in procedure volume, higher da Vinci system placements, and an increase in the installed base of systems.

Fourth quarter 2025 instruments and accessories revenue increased by 17% to \$1.66 billion, compared with \$1.41 billion in the fourth quarter of 2024. The increase in instruments and accessories revenue was primarily driven by approximately 17% growth in da Vinci procedure volume and approximately 44% growth in Ion procedure volume.

Fourth quarter 2025 systems revenue was \$786 million, compared with \$655 million in the fourth quarter of 2024. The higher systems revenue reflected increased da Vinci system placements, a higher lease installed base, and higher da Vinci system average selling prices compared with the fourth quarter of 2024. The Company placed 532 da Vinci surgical systems, of which 303 were da Vinci 5 systems, in the fourth quarter of 2025, compared with 493 systems, of which 174 were da Vinci 5 systems, in the fourth quarter of 2024. The fourth quarter 2025 da Vinci surgical system placements included 250 systems placed under operating lease arrangements, of which 150 systems were placed under usage-based operating lease arrangements, compared with 222 systems placed under operating lease arrangements, of which 140 systems were placed under usage-based operating lease arrangements in the fourth quarter of 2024.

Fourth quarter 2025 GAAP income from operations increased to \$864 million, compared with \$735 million in the fourth quarter of 2024. Fourth quarter 2025 GAAP income from operations included share-based compensation expense of \$207 million, compared with \$180 million in the fourth quarter of 2024. Fourth quarter 2025 non-

GAAP* income from operations increased to \$1.07 billion, compared with \$0.93 billion in the fourth quarter of 2024.

Fourth quarter 2025 GAAP net income attributable to Intuitive Surgical, Inc. was \$795 million, or \$2.21 per diluted share, compared with \$686 million, or \$1.88 per diluted share, in the fourth quarter of 2024. Fourth quarter 2025 GAAP net income attributable to Intuitive Surgical, Inc. included excess tax benefits of \$43 million, or \$0.12 per diluted share, compared with \$34 million, or \$0.09 per diluted share, in the fourth quarter of 2024. Additionally, fourth quarter 2025 GAAP net income included a discrete tax benefit of \$23 million, or \$0.06 per diluted share, arising from the release of unrecognized tax benefits due to statute expiration in various jurisdictions, compared with \$19 million, or \$0.05 per diluted share, in the fourth quarter of 2024.

Fourth quarter 2025 non-GAAP* net income attributable to Intuitive Surgical, Inc. was \$914 million, or \$2.53 per diluted share, compared with \$805 million, or \$2.21 per diluted share, in the fourth quarter of 2024. Fourth quarter 2025 non-GAAP* net income included a discrete tax benefit of \$11 million, or \$0.03 per diluted share, arising from the release of unrecognized tax benefits due to statute expiration in various jurisdictions, compared with \$8 million, or \$0.02 per diluted share, in the fourth quarter of 2024.

The Company ended the fourth quarter of 2025 with \$9.03 billion in cash, cash equivalents, and investments, an increase of \$0.60 billion during the quarter, primarily driven by cash generated from operations, partially offset by cash used for repurchases of common stock and capital expenditures.

2026 Financial Outlook

The Company expects the following results for the full year of 2026:

- Worldwide da Vinci procedure growth of approximately 13% to 15% in 2026, compared to 18% in 2025.
- Non-GAAP* gross profit margin to be within a range of 67% and 68% of revenue in 2026, compared to 67.6% in 2025. This range includes an estimated impact from tariffs of 1.2% of revenue, plus or minus 10 basis points.
- Non-GAAP* operating expense growth of 11% to 15% in 2026, compared to 12% in 2025.

The range for expected non-GAAP* gross profit margin reflects the Company's estimates of the adverse impact from tariffs that are currently in effect as of the time of this press release and assumes such tariffs remain in place. Should additional tariffs be implemented or existing tariffs be modified, the additional impact on the Company's financial results in 2026, including the change in expected non-GAAP* gross profit margin, could be material. The ultimate effect of tariffs will depend on various factors, including the proportion of components procured and finished goods manufactured outside of the United States and the amount, scope, nature, and timing of the tariffs.

The 2026 financial outlook provided above includes forward-looking, non-GAAP financial measures, which management uses in measuring performance. We do not provide a reconciliation of non-GAAP outlook measures to corresponding GAAP measures on a forward-looking basis, because we are unable to predict with reasonable certainty the exact timing and ultimate outcome of certain items, including but not limited to legal proceedings, without unreasonable efforts. These items are uncertain, depend on various factors, and could be material to Intuitive's results computed in accordance with GAAP. For additional information regarding the nature of these items, refer to the reconciliations of historical GAAP to non-GAAP measures included elsewhere in this release.

Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at <https://isrg.gcs-web.com/>.

Webcast and Conference Call Information

Intuitive will hold a teleconference at 1:30 p.m. PDT today to discuss the fourth quarter 2025 financial results. The call will be webcast live and can be accessed on Intuitive's website at www.intuitive.com. For those individuals planning to participate on the call, registration can be completed online at <https://edge.media-server.com/mmc/p/87d7r3w6/> to receive dial-in details and an individual pin. The webcast replay of the call will be made available on our website at www.intuitive.com within 24 hours after the end of the live teleconference and will be accessible for at least 30 days.

About Intuitive

Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical systems and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help

physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most.

Product and brand names/logos are trademarks or registered trademarks of Intuitive or their respective owner. See www.intuitive.com/trademarks.

For more information, please visit the Company's website at www.intuitive.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “goals,” “seeks,” “potential,” “targeted,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of the Company's management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to the following: statements related to future results of operations, including expected procedure growth in 2026, expected non-GAAP gross profit margins in 2026, and expected non-GAAP operating expense growth in 2026; future financial position; and the estimated impact from tariffs. These forward-looking statements should be considered in light of various important factors, including, but not limited to, the following: the overall macroeconomic environment, which may impact customer spending and the Company's costs, including tariffs, the levels of inflation, and interest rates; the conflict between Ukraine and Russia; conflicts in the Middle East; disruption to the Company's supply chain, including difficulties in obtaining a sufficient supply of materials; curtailed or delayed capital spending by hospitals; the impact of global and regional economic and credit market conditions on healthcare spending; delays in obtaining new product approvals, clearances, or certifications from the United States (“U.S.”) Food and Drug Administration (“FDA”), comparable regulatory authorities, or notified bodies; the risk of the Company's inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and customer acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; the Company's completion of and ability to successfully integrate acquisitions; intellectual property positions and litigation; risks associated with the Company's operations and any expansion outside of the U.S.; unanticipated manufacturing disruptions or the inability to meet demand for products; the Company's reliance on sole- and single-sourced suppliers; the results of legal proceedings to which the Company is or may become a party; adverse publicity regarding the Company and the safety of the Company's products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements (including changes to tariffs imposed by the U.S. on imports from various countries, including Mexico, where the Company currently manufactures a significant majority of its instruments and accessories, Germany, where the Company currently manufactures a majority of its endoscopes, and China, where the Company currently imports certain materials); and other risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company's other filings with the Securities and Exchange Commission. The Company's actual results may differ materially and adversely from those expressed in any forward-looking statement, and the Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

*About Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company uses the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive, and non-GAAP net income per diluted share attributable to Intuitive (“EPS”). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance by excluding items such as amortization of intangible assets, share-based compensation (“SBC”) and long-term incentive plan (“LTIP”) expenses, and other special items. LTIP expense relates to phantom share awards granted in China by the Company’s Intuitive-Fosun joint venture to its employees that vest over four years and can remain outstanding for seven to ten years. These awards are valued based on certain key performance metrics. Accordingly, they are subject to significant volatility based on the performance of these metrics and are not tied to performance of the Company’s business within the period. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to its historical performance. The Company believes these non-GAAP financial measures are useful to investors, because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Company’s business.

Non-GAAP gross profit. The Company defines non-GAAP gross profit as gross profit, excluding SBC and LTIP expenses and amortization of intangible assets.

Non-GAAP income from operations. The Company defines non-GAAP income from operations as income from operations, excluding SBC and LTIP expenses, amortization of intangible assets, litigation charges, and gains on the sale of a business.

Non-GAAP net income attributable to Intuitive and EPS. The Company defines non-GAAP net income as net income attributable to Intuitive, excluding SBC and LTIP expenses, amortization of intangible assets, litigation charges, gains on the sale of a business, gains or losses on strategic investments, tax adjustments, including the excess tax benefits associated with SBC arrangements and the net tax effects related to intra-entity transfers of non-inventory assets, and adjustments attributable to noncontrolling interest in joint venture, net of the related tax effects. The Company excludes the excess tax benefits associated with SBC arrangements as well as the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers, because the Company does not believe these items correlate with the ongoing results of its core operations. The tax effects of the non-GAAP items are determined by applying a calculated non-GAAP effective tax rate, which is commonly referred to as the with-and-without method. Without excluding these tax effects, investors would only see the gross effect that these non-GAAP adjustments had on the Company’s operating results. The Company’s calculated non-GAAP effective tax rate is generally higher than its GAAP effective tax rate. The Company defines non-GAAP EPS as non-GAAP net income attributable to Intuitive divided by diluted shares outstanding, which are calculated as GAAP weighted-average outstanding shares plus dilutive potential shares outstanding during the period.

There are a number of limitations related to the use of non-GAAP measures versus measures calculated in accordance with GAAP. Non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive, and non-GAAP EPS exclude items such as SBC and LTIP expenses, amortization of intangible assets, excess tax benefits associated with SBC arrangements, and non-cash amortization of deferred tax assets related to intra-entity transfers of non-inventory assets, which are primarily recurring items. SBC expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business. In addition, the components of the costs that the Company excludes in its calculation of non-GAAP net income attributable to Intuitive and non-GAAP EPS may differ from the components that its peer companies exclude when they report their results of operations. Management addresses these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income attributable to Intuitive and non-GAAP EPS and evaluating non-GAAP net income attributable to Intuitive and non-GAAP EPS together with net income attributable to Intuitive and net income per share attributable to Intuitive calculated in accordance with GAAP.

INTUITIVE SURGICAL, INC.
UNAUDITED QUARTERLY CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(IN MILLIONS, EXCEPT PER SHARE DATA)

	Three Months Ended		
	December 31, 2025	September 30, 2025	December 31, 2024
Revenue:			
Instruments and accessories	\$ 1,658.3	\$ 1,518.8	\$ 1,411.5
Systems	785.9	590.4	654.6
Services	422.0	395.9	347.4
Total revenue	2,866.2	2,505.1	2,413.5
Cost of revenue:			
Product	809.8	699.4	663.9
Service	152.1	143.3	107.4
Total cost of revenue	961.9	842.7	771.3
Gross profit	1,904.3	1,662.4	1,642.2
Operating expenses:			
Selling, general and administrative ⁽¹⁾	687.1	573.3	612.6
Research and development	352.9	329.4	294.7
Total operating expenses	1,040.0	902.7	907.3
Income from operations ⁽²⁾	864.3	759.7	734.9
Interest and other income (expense), net	91.3	95.5	74.9
Income before taxes	955.6	855.2	809.8
Income tax expense (benefit) ⁽³⁾	156.1	146.0	121.8
Net income	799.5	709.2	688.0
Less: net income attributable to noncontrolling interest in joint venture	4.7	4.8	2.3
Net income attributable to Intuitive Surgical, Inc.	\$ 794.8	\$ 704.4	\$ 685.7
Net income per share attributable to Intuitive Surgical, Inc.:			
Basic	\$ 2.24	\$ 1.98	\$ 1.92
Diluted ⁽⁴⁾	\$ 2.21	\$ 1.95	\$ 1.88
Weighted average shares outstanding:			
Basic	354.9	356.6	356.4
Diluted	360.4	361.8	363.9
⁽¹⁾ Selling, general and administrative includes the effect of the following item:			
Contribution to the Intuitive Foundation	\$ 70.0	\$ —	\$ 45.0
⁽²⁾ Income from operations includes the effect of the following items:			
Amortization of intangible assets	\$ (3.3)	\$ (3.3)	\$ (3.1)
Expensed IP charged to R&D	\$ —	\$ (0.6)	\$ (5.7)
⁽³⁾ Income tax expense (benefit) includes the effect of the following items:			
Excess tax benefits related to share-based compensation arrangements	\$ (43.0)	\$ (24.2)	\$ (34.3)
Discrete tax benefit from release of unrecognized tax benefits	\$ (22.5)	\$ (22.5)	\$ (18.9)
⁽⁴⁾ Diluted net income per share attributable to Intuitive Surgical, Inc. includes the effect of the following items:			
Contribution to the Intuitive Foundation, net of tax	\$ (0.15)	\$ —	\$ (0.10)
Amortization of intangible assets, net of tax	\$ (0.01)	\$ (0.01)	\$ (0.01)
Expensed IP charged to R&D, net of tax	\$ —	\$ —	\$ (0.01)
Excess tax benefits related to share-based compensation arrangements	\$ 0.12	\$ 0.07	\$ 0.09
Discrete tax benefit from release of unrecognized tax benefits	\$ 0.06	\$ 0.06	\$ 0.05

INTUITIVE SURGICAL, INC.
UNAUDITED ANNUAL CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(IN MILLIONS, EXCEPT PER SHARE DATA)

	Years Ended December 31,	
	2025	2024
Revenue:		
Instruments and accessories	\$ 6,018.9	\$ 5,079.0
Systems	2,473.7	1,966.0
Services	1,572.1	1,307.1
Total revenue	10,064.7	8,352.1
Cost of revenue:		
Product	2,866.1	2,313.1
Service	556.3	404.8
Total cost of revenue	3,422.4	2,717.9
Gross profit	6,642.3	5,634.2
Operating expenses:		
Selling, general and administrative ⁽¹⁾	2,385.0	2,140.0
Research and development	1,311.8	1,145.3
Total operating expenses	3,696.8	3,285.3
Income from operations ⁽²⁾	2,945.5	2,348.9
Interest and other income, net	365.9	324.9
Income before taxes	3,311.4	2,673.8
Income tax expense ⁽³⁾	434.8	336.3
Net income	2,876.6	2,337.5
Less: net income attributable to noncontrolling interest in joint venture	20.6	14.9
Net income attributable to Intuitive Surgical, Inc.	\$ 2,856.0	\$ 2,322.6
Net income per share attributable to Intuitive Surgical, Inc.:		
Basic	\$ 8.00	\$ 6.54
Diluted ⁽⁴⁾	\$ 7.87	\$ 6.42
Weighted average shares outstanding:		
Basic	356.9	355.2
Diluted	362.7	362.0
⁽¹⁾ Selling, general and administrative includes the effect of the following item:		
Contribution to the Intuitive Foundation	\$ 70.0	\$ 45.0
⁽²⁾ Income from operations includes the effect of the following items:		
Amortization of intangible assets	\$ (13.2)	\$ (16.7)
Expensed IP charged to R&D	\$ (7.0)	\$ (5.9)
⁽³⁾ Income tax expense includes the effect of the following items:		
Excess tax benefits related to share-based compensation arrangements	\$ (245.5)	\$ (223.3)
Discrete tax benefit from release of unrecognized tax benefits	\$ (45.5)	\$ (27.0)
⁽⁴⁾ Diluted net income per share attributable to Intuitive Surgical, Inc. includes the effect of the following items:		
Contribution to the Intuitive Foundation, net of tax	\$ (0.15)	\$ (0.10)
Amortization of intangible assets, net of tax	\$ (0.03)	\$ (0.04)
Expensed IP charged to R&D, net of tax	\$ (0.02)	\$ (0.01)
Excess tax benefits related to share-based compensation arrangements	\$ 0.68	\$ 0.62
Discrete tax benefit from release of unrecognized tax benefits	\$ 0.13	\$ 0.07

INTUITIVE SURGICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(IN MILLIONS)

	December 31, 2025	December 31, 2024
Cash, cash equivalents, and investments	\$ 9,034.1	\$ 8,832.4
Accounts receivable, net	1,527.3	1,225.4
Inventory	1,840.0	1,487.2
Property, plant, and equipment, net	5,342.4	4,646.6
Goodwill	370.3	347.5
Deferred tax assets	1,018.6	1,045.1
Other assets	1,326.0	1,159.0
Total assets	<u>\$ 20,458.7</u>	<u>\$ 18,743.2</u>
Accounts payable and other liabilities	\$ 1,918.9	\$ 1,690.7
Deferred revenue	598.1	522.9
Total liabilities	<u>2,517.0</u>	<u>2,213.6</u>
Stockholders' equity	<u>17,941.7</u>	<u>16,529.6</u>
Total liabilities and stockholders' equity	<u>\$ 20,458.7</u>	<u>\$ 18,743.2</u>

INTUITIVE SURGICAL, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(IN MILLIONS, EXCEPT PER SHARE DATA)

	Three Months Ended			Years Ended	
	December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024
GAAP gross profit	\$ 1,904.3	\$ 1,662.4	\$ 1,642.2	\$ 6,642.3	\$ 5,634.2
Share-based compensation expense	35.5	38.8	33.6	147.1	123.7
Long-term incentive plan expense	(0.1)	0.2	0.2	0.5	0.8
Amortization of intangible assets	2.4	2.4	2.4	9.7	12.3
Non-GAAP gross profit	<u>\$ 1,942.1</u>	<u>\$ 1,703.8</u>	<u>\$ 1,678.4</u>	<u>\$ 6,799.6</u>	<u>\$ 5,771.0</u>
GAAP income from operations	\$ 864.3	\$ 759.7	\$ 734.9	\$ 2,945.5	\$ 2,348.9
Share-based compensation expense	203.2	203.5	177.0	788.1	676.8
Long-term incentive plan expense	(1.4)	1.3	1.2	1.0	5.6
Amortization of intangible assets	3.3	3.3	3.1	13.2	16.7
Litigation charges	2.0	8.1	12.6	13.6	19.8
Gain on sale of business	(1.0)	—	(1.1)	(1.0)	(1.1)
Non-GAAP income from operations	<u>\$ 1,070.4</u>	<u>\$ 975.9</u>	<u>\$ 927.7</u>	<u>\$ 3,760.4</u>	<u>\$ 3,066.7</u>
GAAP net income attributable to Intuitive Surgical, Inc.	\$ 794.8	\$ 704.4	\$ 685.7	\$ 2,856.0	\$ 2,322.6
Share-based compensation expense	203.2	203.5	177.0	788.1	676.8
Long-term incentive plan expense	(1.4)	1.3	1.2	1.0	5.6
Amortization of intangible assets	3.3	3.3	3.1	13.2	16.7
Litigation charges	2.0	8.1	12.6	13.6	19.8
Gain on sale of business	(1.0)	—	(1.1)	(1.0)	(1.1)
(Gains) losses on strategic investments	(4.9)	(3.0)	12.7	(2.9)	9.2
Tax adjustments ⁽¹⁾	(82.7)	(49.9)	(86.0)	(427.0)	(391.5)
Adjustments attributable to noncontrolling interest in joint venture	0.3	(0.5)	(0.5)	(0.8)	(2.2)
Non-GAAP net income attributable to Intuitive Surgical, Inc.	<u>\$ 913.6</u>	<u>\$ 867.2</u>	<u>\$ 804.7</u>	<u>\$ 3,240.2</u>	<u>\$ 2,655.9</u>
GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted	\$ 2.21	\$ 1.95	\$ 1.88	\$ 7.87	\$ 6.42
Share-based compensation expense	0.56	0.56	0.49	2.17	1.87
Long-term incentive plan expense	—	0.01	—	—	0.02
Amortization of intangible assets	0.01	0.01	0.01	0.04	0.05
Litigation charges	—	0.02	0.03	0.04	0.05
Gain on sale of business	—	—	—	—	—
(Gains) losses on strategic investments	(0.02)	(0.01)	0.04	(0.01)	0.02
Tax adjustments ⁽¹⁾	(0.23)	(0.14)	(0.24)	(1.18)	(1.08)
Adjustments attributable to noncontrolling interest in joint venture	—	—	—	—	(0.01)
Non-GAAP net income per share attributable to Intuitive Surgical, Inc. - diluted	<u>\$ 2.53</u>	<u>\$ 2.40</u>	<u>\$ 2.21</u>	<u>\$ 8.93</u>	<u>\$ 7.34</u>

⁽¹⁾ For the three months ended December 31, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of \$(43.0) million, or \$(0.12) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of \$10.6 million, or \$0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of \$(50.3) million, or \$(0.14) per diluted share. For the three months ended December 31, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of \$(34.3) million, or \$(0.09) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of \$10.2 million, or \$0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of \$(61.9) million, or \$(0.18) per diluted share.

For the twelve months ended December 31, 2025, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of \$(245.5) million, or \$(0.68) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of \$42.6 million, or \$0.12 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of \$(224.1) million, or \$(0.62) per diluted share. For the twelve months ended December 31, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of \$(223.3) million, or \$(0.62) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of \$40.7 million, or \$0.11 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of \$(208.9) million, or \$(0.57) per diluted share.